Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, Wegovy
Novo’s Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next.
Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions. Approval in the U.S.–Novo’s biggest market for obesity drugs–by the Food and Drug Administration could be next.
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
Zacks.com on MSN
12h
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
Novo Nordisk A/S NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) ...
STAT
7d
Compounded semaglutide is an ill-defined public health crisis
Grappling with obesity and the metabolic diseases cascading from it, they are now among the plurality of Americans who have ...
Medscape
14h
Semaglutide Bests Liraglutide in Long-Term Weight Loss
Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...
11d
Wegovy, Ozempic may someday be available as monthly injection
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...
Everyday Health
7d
Wegovy May Reduce the Risk of Death From COVID-19, Study Suggests
A new study found that people taking Wegovy during the pandemic were 33 percent less likely to die of COVID-19.
STAT
2d
Pharmalittle: We’re reading about a rare-disease drug bill, compounded Wegovy, and more
For patients on a 12-month plan, Hims offers a
semaglutide
injection for $199 a month. Ozempic and
Wegovy
carry high list prices of $935.77 and $1,349.02, respectively, for a month’s supply, ...
BioSpace
9d
What Expanded CVD Medicare Coverage May Mean for Novo Nordisk’s Wegovy
A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, ...
Medscape
7d
Semaglutide Reduces MACE, Death in Participants With CVD, Overweight/Obesity, and Impaired Kidney Function
A SELECT trial subanalysis showed that semaglutide works as well in people with CVD, overweight/obesity, and impaired kidney ...
healthday on MSN
11d
Wegovy, Ozempic May Someday Be Given as Once-Monthly Injection
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of ...
The Pharma Letter
17h
Wegovy label should be extended, CHMP recommends
The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
European Union
Novo Nordisk
Heart failure with preserved ejection fraction
Ozempic
Committee for Medicinal Products for Human Use
Feedback